BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Fate Therapeutics 

10931 North Torrey Pines Road
Suite 107
La Jolla  California  92037  U.S.A.
Phone: n/a Fax: n/a


SEARCH JOBS




Industry
Biotechnology

Segment
Start Up





 Company News
Fate Therapeutics (FATE) to Webcast Conference Call Reporting Third Quarter 2013 Financial Results on November 13, 2013 11/7/2013 9:54:49 AM
Fate Therapeutics (FATE) to Present at World Muscle Society Congress 10/3/2013 9:49:42 AM
Fate Therapeutics (FATE) Bombs in IPO Debut, Prices at Low End of Revised Range 10/1/2013 9:31:27 AM
Orphan Disease Biotech Fate Therapeutics Files for a $69 Million IPO 8/14/2013 8:39:00 AM
Fate Therapeutics Presents Preclinical Efficacy Data for WNT7A-Analog Program at Muscular Dystrophy Association 2013 Scientific Conference 4/22/2013 1:28:56 PM
Fate Therapeutics Strengthens Leadership Position in the Development of Wnt-based Protein Therapeutics 12/4/2012 9:40:48 AM
Fate Therapeutics Initiates Phase 2 Clinical Study of ProHema for the Treatment of Hematologic Malignancies 11/27/2012 8:51:32 AM
Fate Therapeutics Names Christian Weyer New CEO 10/15/2012 7:26:34 AM
Fate Therapeutics Raises $9.2 Million for Stem Cell Treatments 8/23/2012 8:27:51 AM
Fate Therapeutics And BD Biosciences (BDX) Launch BD(TM) SMC4 to Improve Cellular Reprogramming and IPS Cell Culture Applications 6/11/2012 12:01:48 PM
12345